- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05195450
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load - a Randomized Controlled Trial
The main goal of therapy for patients with chronic HBV infection with no significant liver disease is to improve survival and quality of life by preventing disease progression, development of liver cirrhosis and consequently HCC development. The likelihood of achieving these goals depends on the timing of therapy during the natural course of the infection but also on the stage of the disease and the patients' age when treatment is started. The inhibition of viral replication and normalization of ALT by antiviral treatment has been shown to achieve the elimination of chronic HBV-induced necroinflammatory activity and progressive fibrotic liver progression in the vast majority of patients, in turn reducing the risk of HCC. Even in HBeAg positive patients, treatment-induced HBeAg loss and seroconversion to antiHBe characterizes the induction of a partial immune control often leading to a low replicative phase of the chronic HBV infection and good outcomes.
Treatment in chronic HBV infection is indicated in - presence of advanced fibrosis/cirrhosis (LSM >11 KPA) or patients with significant fibrosis (LSM >8 or APRI >1.5 or >F2 on liver biopsy) with high viral load (>2000 IU/ml) or significantly elevated ALT (x2 ULN). Presence of any of these factors is known to increase the risk of development of cirrhosis and hepatocellular carcinoma. TAF in non-cirrhotic patients (LSM <8 KPA) with normal ALT and low viral load (HBV DNA <2000 IU/ml) (currently treatment ineligible) as compared to delayed initiation (on demand) might reduce HCC risk, progression of liver fibrosis and reduction in HBsAg levels. As TAF is known to have favorable effects on the overall long-term outcome, the main clinical challenge is to identify the patients at risk of HCC and cirrhosis who warrant early antiviral therapy.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Aim and Objective - To study the safety and efficacy of TAF as compared to initiation based on current criteria in patients with non-cirrhotic chronic HBV infection and normal ALT and low viral load.
Methodology:
Study population: The study will be conducted on the treatment naïve consecutive patients having non-cirrhotic chronic HBV infection and normal ALT and low viral load seen at the outpatient clinics/wards of Department of Hepatology, ILBS, New Delhi.
Study design:
• A prospective, randomized, single center open label study.
Study period: 5 years from the last patient enrollment
Sample size with justification: All consecutive cases consenting to be a participant in this study and meeting inclusion and exclusion criteria will be enrolled. Considering the incidence of 20% for the composite end-point in patients without TAF and 5% for patients on TAF, with power of 80% and alpha error of 5%, 176 patients (88 patients in each arm) need to be enrolled. Considering the attrition rate of ~15%, we decide to enroll 100 patients in each arm.
Intervention
- TAF 25 mg OD vs no treatment x 5 years and beyond
- Tests - Baseline - USG abdomen, ALT, Creatinine, DEXA, HBVDNA, HBeAg, HBsAg (quant), Fibroscan
- 6 monthly - ALT
- 1 yearly - USG abdomen, ALT, Creatinine, DEXA, HBVDNA, HBeAg, HBsAg (quant), Fibroscan
- No liver biopsy
Statistical Analysis:
Data will be reported as mean + SD. Categorical variables will be compared using the chi-square test or Fisher exact test. Normal continuous variables will be compared using the Student's t test Non normal continuous variables will be compared using the Mann Whitney rank-sum test (unpaired data) or the Wilcoxon test (paired data). The actuarial probability of survival will be calculated by the Kaplan-Meier method and compared using the log-rank test. A Cox regression analysis will be performed to identify independent prognostic factors for survival. Univariate and multivariate analysis will be used whenever applicable.
Adverse effects:
Most common- headache, nausea, and fatigue; (1% to 10%): Abdominal pain, nausea, diarrhea, dyspepsia, elevated serum amylase, vomiting, flatulence, abdominal distension; Common (1% to 10%): Rash, pruritus, elevated ALT; Uncommon (0.1% to 1%): Treatment ALT flares.
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Dr Ankur Jindal, DM
- Telefonnummer: 01146300000
- E-post: ankur.jindal3@gmail.com
Studieorter
-
-
Delhi
-
New Delhi, Delhi, Indien, 110070
- Rekrytering
- Institute of Liver & Biliary Sciences (ILBS)
-
Kontakt:
- Dr Ankur Jindal, DM
- Telefonnummer: 01146300000
- E-post: ankur.jindal3@gmail.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- HBsAg+
- Persistent normal ALT 3-6m apart (<30 IU/ml in male and <20 IU/ml in female)
- HBV DNA < 2000 IU/ml
- LSM <8 Kpa
Exclusion Criteria:
- Prior NUC/IFN exposure
- Renal dysfunction (Serum Creatinine >1.5 mg/dl)
- Known liver cirrhosis/ esophageal varices
- Any clinical decompensation (CD)
- Pre-existing hepatocellular carcinoma
- Pregnancy
- Healthcare workers (HCW)
- Post transplant, patients with advance malignancy or on chemotherapy
- Co-infections - Hepatitis C, Hepatitis D, Human immunodeficiency virus
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Tenofovir Alafenamide Fumarate
• TAF 25 mg OD vs no treatment x 5 years and beyond
|
• TAF 25 mg OD vs no treatment x 5 years and beyond
|
Inget ingripande: No Treatment Arm
No treatment
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of patients with HBV DNA <2000 IU/ml, normal ALT and no significant fibrosis (as per APASL 2015).
Tidsram: upto 5 Years
|
Any two of the following -
|
upto 5 Years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Incidence of HCC
Tidsram: upto 3 years
|
upto 3 years
|
Incidence of HCC
Tidsram: upto 5 years
|
upto 5 years
|
Percentage of patients with LSM >8 Kpa
Tidsram: upto 5 Years
|
upto 5 Years
|
Percentage of patients with LSM >11 Kpa
Tidsram: upto 5 Years
|
upto 5 Years
|
Number of subjects with no progression of fibrosis
Tidsram: upto 5 Years
|
upto 5 Years
|
Percentage of patients with APRI score >1.5 and >2
Tidsram: upto 5 Years
|
upto 5 Years
|
Percentage of patients with HBV DNA >2000 IU/ml
Tidsram: upto 5 Years
|
upto 5 Years
|
Percentage of patients with undetectable HBV DNA
Tidsram: upto 5 Years
|
upto 5 Years
|
Percentage of patients with HBsAg loss and HBsAg seroconversion
Tidsram: upto 5 Years
|
upto 5 Years
|
Log HBsAg reduction
Tidsram: upto 5 Years
|
upto 5 Years
|
Percentage of patients with HBeAg loss and HBeAg seroconversion in HBeAg+ chronic hepatitis B
Tidsram: upto 5 Years
|
upto 5 Years
|
Percentage of patients with ALT > ULN, >2 times and 5 times ULN
Tidsram: upto 5 Years
|
upto 5 Years
|
Treatment related adverse effects of TAF
Tidsram: upto 5 Years
|
upto 5 Years
|
Non-compliant to treatment or monitoring
Tidsram: upto 5 years
|
upto 5 years
|
Death
Tidsram: upto 5 years
|
upto 5 years
|
Treatment related severe adverse effects
Tidsram: upto 5 years
|
upto 5 years
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Hepatit, Viral, Human
- Hepadnaviridae-infektioner
- DNA-virusinfektioner
- Hepatit, kronisk
- Hepatit
- Leversjukdomar
- Hepatit B
- Hepatit B, kronisk
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Omvända transkriptashämmare
- Nukleinsyrasynteshämmare
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- Tenofovir
Andra studie-ID-nummer
- ILBS-HBV-02
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Non-cirrhotic, Chronic Hepatitis B
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Har inte rekryterat ännuLymfom | Lymfom, icke-Hodgkin | Non-Hodgkins lymfom | Non-Hodgkin lymfom | Refraktärt B-cells non-Hodgkin-lymfom | Refraktärt non-Hodgkin lymfom | Höggradigt B-cellslymfom | CNS lymfom | Lymfom Non-Hodgkins B-cell | Återfall av non-Hodgkin-lymfom | Lymfom, icke-Hodgkins | Stort B-cellslymfom | Lymfom, Non-Hodgkins... och andra villkor
-
Caribou Biosciences, Inc.RekryteringLymfom | Lymfom, icke-Hodgkin | B-cellslymfom | Non Hodgkin lymfom | Refraktärt B-cells non-Hodgkin-lymfom | Återfall av non Hodgkin-lymfom | B-cells non-Hodgkins lymfomFörenta staterna, Australien, Israel
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekryteringRefraktärt B-cells non-Hodgkin-lymfom | Återkommande B-cells non-Hodgkin lymfom | Höggradigt B-cells non-Hodgkins lymfom | Non-Hodgkins lymfom av medelgrad B-cellFörenta staterna
-
National Cancer Institute (NCI)RekryteringRefraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande transformerat non-Hodgkin-lymfom | Återkommande non-Hodgkin lymfom | Refraktärt non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant... och andra villkorFörenta staterna
-
University of NebraskaBristol-Myers SquibbRekryteringFollikulärt lymfom | Refraktärt non-Hodgkin lymfom | Höggradigt B-cellslymfom | DLBCL - Diffust stort B-cellslymfom | Återfall av non-Hodgkin-lymfom | Mediastinalt stort B-cellslymfom | Indolent B-cell non-Hodgkin lymfomFörenta staterna
-
Mayo ClinicHar inte rekryterat ännuIndolent B-cell non-Hodgkin lymfom | Återkommande indolent non-Hodgkin-lymfom | Refraktärt indolent non-Hodgkin-lymfom | Återkommande indolent B-cell non-Hodgkin lymfom | Refraktärt indolent B-cell non-Hodgkin lymfomFörenta staterna
-
Affimed GmbHAvslutadRefraktärt B-cells non-Hodgkin-lymfom | Återfall av B-cells non-Hodgkin-lymfomFörenta staterna, Tjeckien, Tyskland, Polen
-
ADC Therapeutics S.A.RekryteringB-cells non-Hodgkin lymfom | Refraktärt B-cells non-Hodgkin-lymfom | Återfall av B-cells non-Hodgkin-lymfomFörenta staterna, Spanien, Italien, Storbritannien, Belgien, Tjeckien
-
CARsgen Therapeutics Co., Ltd.RenJi Hospital; First Affiliated Hospital of Zhejiang UniversityAvslutadRefraktärt B-cells non-Hodgkin-lymfom | Återfall av B-cell non-Hodgkin lymfomKina
-
The Lymphoma Academic Research OrganisationRoche Pharma AGAvslutadRefraktärt B-cells non-Hodgkin-lymfom | Återkommande B-cells non-Hodgkin lymfomFrankrike
Kliniska prövningar på Tenofovir alafenamide fumarate
-
Nucorion Pharmaceuticals, Inc.Ligand PharmaceuticalsAvslutadKronisk hepatit BFörenta staterna
-
SpectraCure ABRekryteringÅterkommande prostatacancerFörenta staterna, Kanada, Storbritannien, Sverige
-
University Hospital Inselspital, BerneAvslutad
-
Kaohsiung Medical University Chung-Ho Memorial...OkändHepatit B | Fibros och levercirrosTaiwan
-
University Health Network, TorontoGilead Sciences; University of Modena and Reggio Emilia; San Raffaele University... och andra samarbetspartnersAvslutad
-
Massachusetts General HospitalGilead SciencesIndragenTrötthet | Multipel skleros, skov-remitterandeFörenta staterna
-
Thomas Jefferson UniversityGilead SciencesAktiv, inte rekryterande
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)AvslutadMalign fast neoplasma | Hepatit B-infektionFörenta staterna, Guam
-
Thomas Jefferson UniversityAvslutadHyperglykemi | Hjärt-kärlsjukdomar | Metaboliskt syndrom | Viktökning | HIV-1-infektion | Onormal njurfunktionFörenta staterna
-
University Health Network, TorontoRekrytering